Oramed Pharmaceuticals Inc. — Director's Dealing 2021

Aug 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2021-08-09

Reporting Person: RAKIN KEVIN (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-09	Common Stock	M	5697	$6.23	Acquired	20758	Direct
2021-08-09	Common Stock	F	1683	$21.09	Disposed	19075	Direct
2021-08-09	Common Stock	M	6666	$4.80	Acquired	25741	Direct
2021-08-09	Common Stock	F	1517	$21.09	Disposed	24224	Direct
2021-08-09	Common Stock	M	10000	$4.17	Acquired	34224	Direct
2021-08-09	Common Stock	F	1977	$21.09	Disposed	32247	Direct
2021-08-09	Common Stock	M	56773	$7.77	Acquired	89020	Direct
2021-08-09	Common Stock	F	20916	$21.09	Disposed	68104	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-09	Stock Option (right to buy)	$6.23	M	5697	Disposed	2027-02-09	Common Stock (5697)	Direct
2021-08-09	Stock Option (right to buy)	$4.80	M	6666	Disposed	2030-01-08	Common Stock (6666)	Direct
2021-08-09	Stock Option (right to buy)	$4.17	M	10000	Disposed	2029-09-11	Common Stock (10000)	Direct
2021-08-09	Stock Option (right to buy)	$7.77	M	56773	Disposed	2027-06-30	Common Stock (56773)	Direct

Footnotes

F1: Represents a cashless exercise of outstanding stock options to purchase 5,697 shares of common stock. The reporting person received 4,014 shares of common stock and surrendered 1,683 shares of common stock underlying the stock option in payment of the exercise price.

F2: Represents a cashless exercise of outstanding stock options to purchase 6,666 shares of common stock. The reporting person received 5,149 shares of common stock and surrendered 1,517 shares of common stock underlying the stock option in payment of the exercise price.

F3: Represents a cashless exercise of outstanding stock options to purchase 10,000 shares of common stock. The reporting person received 8,023 shares of common stock and surrendered 1,977 shares of common stock underlying the stock option in payment of the exercise price.

F4: Represents a cashless exercise of outstanding stock options to purchase 56,773 shares of common stock. The reporting person received 35,857 shares of common stock and surrendered 20,916 shares of common stock underlying the stock option in payment of the exercise price.

F5: The options vested as follows: 15,591 vested on December 31, 2017, 2018 and 2019 and additional 10,000 vested on December 31, 2020.